Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : qtrn(quintiles trans) -- Ignore unavailable to you. Want to Upgrade?

To: Rich Doherty who wrote (4)	2/9/1998 1:33:00 PM
From: mrc	Respond to of 105

Hi Rich, Bought some last week and happy to see it moved up nicely today. I think we are all alone. Regards, Rosalie

To: Rich Doherty who wrote (4)	3/7/1998 3:01:00 PM
From: DTselentis	Read Replies (2) \| Respond to of 105

With the earnings projections for CRO's -- Quintiles included for the next few years this stock should continue to do well. While it is highly valued--- its #1 in its industry segment. The trend for outsourcing is strong within the pharmacetical industry and should expand even further in the future. In addition, the biotech industry is experiencing a dramatic increase in the number of drug candidates that need to be tested in clinical trials. These trends should help companies like Quintiles grow at a good clip for years to come.